Daraxonrasib is going up against standard-of-care chemotherapy, in the second line for metastatic pancreatic cancer (and its being tested as first-line therapy, and in resectable disease, alongside this)
Even after approval, manufacturing ramp-up and commercial launch logistics mean CagriSema likely will not be widely available to patients until the following year
1, fully insured members will need to contact their prescribing doctors to request prior authorization for Saxenda, Wegovy and Zepbound
DSIP DSIP is a peptide studied for its influence on sleep regulation, stress balance, and neurological function
It is essential to emphasise that any use of GLP-1 medications in Hashimoto's patients would be off-label unless the individual also meets criteria for type 2 diabetes or obesity treatment according to the medication's SmPC